share_log

君聖泰醫藥-B:董事會會議召開日期通告

HIGHTIDE-B: NOTICE OF DATE OF BOARD MEETING

HKEX ·  Aug 14 17:41

Summary by Futu AI

君圣泰医药-B(股份代號:2511)將於2024年8月28日(星期三)召開董事會會議,主要目的是審議及批准公司及其附屬公司截至2024年6月30日止六個月的中期業績及其發佈。此次會議將由執行董事兼行政總裁劉利平博士主持,並有其他董事會成員包括執行董事于萌女士;非執行董事朱迅博士、馬立雄先生及江峰先生;以及獨立非執行董事譚擘先生、李靖博士及孔德偉先生參與。會議的召開將有助於股東了解公司的財務狀況及業務發展。
君圣泰医药-B(股份代號:2511)將於2024年8月28日(星期三)召開董事會會議,主要目的是審議及批准公司及其附屬公司截至2024年6月30日止六個月的中期業績及其發佈。此次會議將由執行董事兼行政總裁劉利平博士主持,並有其他董事會成員包括執行董事于萌女士;非執行董事朱迅博士、馬立雄先生及江峰先生;以及獨立非執行董事譚擘先生、李靖博士及孔德偉先生參與。會議的召開將有助於股東了解公司的財務狀況及業務發展。
Kunshengtai Medicine-B (Stock Code: 2511) will hold a board of directors meeting on Wednesday, August 28, 2024 to review and approve the company and its subsidiaries' mid-term performance up to June 30, 2024. The meeting will be chaired by Executive Director and CEO Dr. Liu Liping, and attended by other board members including Executive Director Ms. Yu Meng; non-executive directors Dr. Zhu Xun, Mr. Ma Lixiong, and Mr. Jiang Feng; as well as independent non-executive directors Mr. Tan Biaozheng, Dr. Li Jing, and Mr. Kong Dewei. The meeting will help shareholders to understand the company's financial status and business development.
Kunshengtai Medicine-B (Stock Code: 2511) will hold a board of directors meeting on Wednesday, August 28, 2024 to review and approve the company and its subsidiaries' mid-term performance up to June 30, 2024. The meeting will be chaired by Executive Director and CEO Dr. Liu Liping, and attended by other board members including Executive Director Ms. Yu Meng; non-executive directors Dr. Zhu Xun, Mr. Ma Lixiong, and Mr. Jiang Feng; as well as independent non-executive directors Mr. Tan Biaozheng, Dr. Li Jing, and Mr. Kong Dewei. The meeting will help shareholders to understand the company's financial status and business development.

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.